Background and aims As NSAIDs can cause serious upper gastrointestinal harm, guidelines have been established for the prescribing of proton pump inhibitors (PPIs) in high-risk patients using NSAIDs. Studies examining guideline compliance in surgical patients are scarce. Therefore, a retrospective cross-sectional database study was carried out aimed at determining the proportion of noncompliance with the Dutch guideline and determining the association of several factors with this noncompliance. Materials and methods Hospital admissions of patients on surgical wards of Erasmus University Medical Center between 1 January 2013 and 1 August 2014 were included in which an NSAID was newly prescribed. Preadmission PPI use was excluded. The main outcome was the proportion of noncompliance with the guideline. As a secondary outcome, the association of several potential risk factors with noncompliance was assessed. The proportion of guideline noncompliance was calculated as the percentage of all included surgical ward admissions. For the secondary analysis, univariate and multivariable logistic regression analyses were carried out. 
Introduction
NSAIDs are widely used for their analgesic, antipyretic, and anti-inflammatory effects [1, 2] . Upper gastrointestinal events with clinical symptoms occur in 2.5-4.5% of patients and these are severe in ∼ 1.0-1.5% of patients [3] . As the costs associated with these events are considerable, prevention using gastroprotective strategies may be costeffective, especially in high-risk patients [4] . Therefore, guidelines have been implemented for the prescription of gastroprotective strategies in high-risk patients. In the Netherlands, the guideline 'NSAID use and prevention of gastric toxicity' of the Dutch Institute for Healthcare Improvement from 2003 [5] and the HARM-wrestling recommendations from 2009 [6] are the evidence-based guidelines most broadly used. HARM stands for Hospital Admissions Related to Medication; the HARM-wrestling recommendations were based on the results of the HARM study [7] .
Both guidelines recommend a gastroprotective strategy in high-risk patients (see Table 1 for the recommendations in the guidelines). Comparable guidelines are published in other countries, but they are not always complied with. In the Netherlands, Sturkenboom et al. [8] showed already in 2003 that gastroprotective strategies were underused in patients on NSAIDs. A very recent study showed that gastroprotection use had increased in time, but that there was still room for improvement [9] . These Dutch studies are confirmed by a large US study, also showing underuse of gastroprotection [10] . Another US study showed that reimbursement of medication plays an important role in underuse of gastroprotection [11] .
Besides underutilization of gastroprotective agents, overuse is also common, especially within hospitals [12, 13] . Increasingly, studies on adverse drug reactions caused by proton pump inhibitors (PPIs) are being published, contradicting the overall professional opinion on the high safety of this drug class. Hypomagnesemia [14] , increased fracture risk [15] , hypovitaminosis B 12 [16] , and community-acquired pneumonia [17] have all been linked to PPI use, although the evidence is rarely conclusive. Given these reports, it is becoming increasingly important to only use PPIs when indicated. In hospitals, NSAIDs are often initiated as postoperative analgesics and PPIs are costarted as gastroprotective agents, which may result in chronic PPI use: after the NSAID is stopped, the PPI is continued inadvertently [12] . This makes it all the more important to only add PPIs when strictly indicated. Therefore, we carried out a study aimed at determining the noncompliance with guidelines for prescribing PPIs as gastroprotective agents in NSAID users in surgical patients. The secondary aim was to determine the risk factors associated with guideline noncompliance.
Materials and methods

Study design
A single-center retrospective database study was carried out using data from the electronic patient record (Elpado, noncommercial homegrown system) of the Erasmus University Medical Center (Erasmus MC) in Rotterdam, the Netherlands. All data were handled confidentially. Patient and prescriber identification lists were made and the data were stored in a database in a coded way so that they could not be tracked back to the specific patient or prescriber. The study was carried out according to the Personal Data Protection Act. The Medical Research Ethics Committee of Erasmus MC provided a waiver for the study.
Study population
The study base population comprised all hospital admissions of patients admitted to the surgical wards of Erasmus MC from 1 January 2013 to 31 July 2014, in which the patient received a nonselective NSAID (nsNSAID) [ATC code M01AB, M01AC, M01AE or coxib (ATC code M01AH)] (http://www.whocc.no/atc_ddd_index/). From this base population, a sample of hospital admissions was selected by including each 10th patient, with equal selection of all surgical wards. After reaching the end of the dataset, again every 10th patient of the remaining patients was selected, and so on. Each selected patient was first checked for the following inclusion and exclusion criteria.
Inclusion criteria for admitted patients were 18 years and older of age and starting an NSAID while in hospital. Exclusion criteria were prehospital NSAID use continued during hospitalization, prehospital PPI use continued during hospitalization, or a combination of both, PPI prescription at least 2 h before NSAID prescription in hospital, and dermal NSAID use.
The selection was repeated until 250 eligible hospital admissions were included (see the Data analysis section for sample size collection).
Data collection
Eligible patients were selected from the computerized physician order entry system (Medicator; CSC-Isoft, Leiden, the Netherlands) on the basis of the use of nsNSAIDs or coxibs. General patient and medical data were collected from the electronic patient records: sex, date of birth, date of hospital admission, date of hospital discharge, the physician who prescribed the NSAID (coded by a number), name of surgical ward, name of NSAID, start date of NSAID prescription, stop date of NSAID prescription, daily NSAID dose, NSAID prescribed 'as needed' or not, number of medicines coprescribed with NSAID (NSAID included in counting), whether the patient had a history of a PUOB (peptic ulcer, obstruction, bleeding) or not, whether the patient had a history of untreated Helicobacter pylori infection or not, relevant comorbidities (rheumatoid arthritis, diabetes mellitus, cardiac failure) and how many if applicable, risk medication (according to guideline) present or not and how many, and which class of risk medication if applicable, and PPI use or not, start date, and stop date of PPI use if applicable.
We decided not to include comedication with nonoral anticoagulants or spironolactone as risk medication because neither were included in the alert system of Medicator, which is based on the national G-standard, a system of drug-drug interaction alerts. Therefore, although spironolactone is mentioned in the guidelines as a high-risk medication, the Dutch medication surveillance systems based on the G-standard do not alert for this medication.
High-risk NSAID users and compliance with guideline on NSAID use and PPI prescription High-risk patients were defined according to the guideline of the Dutch Institute for Healthcare Improvement and the HARM-wrestling report [6, 7] . PPIs were assessed as needed when (a) the patient is 70 years of age or older, or has a history of gastric ulcer disease, or is infected with H. pylori or (b) the patient is between 60 and 70 years of age and has additional risk factors as described in the guidelines. Long-term use of high dosages of NSAIDs was not applicable to our population as the NSAIDs were mainly prescribed as a postoperative analgesic. Noncompliance with the guideline was defined as PPI prescription when the patient was not at risk for gastrointestinal toxicity according to the guidelines or PPI prescription when the patient was at risk for gastrointestinal toxicity, but received a coxib (without aspirin as comedication), or no PPI prescription when the patient was at risk for gastrointestinal toxicity according to the guidelines.
The appropriateness of coxib prescription (without a PPI) was not assessed in this study.
Outcome
The primary outcome was noncompliance with PPI prescribing as mentioned in the national evidence-based guidelines on NSAID use and gastroprotection. The secondary outcome was the association of several potential risk factors with noncompliance with the guideline. These potential risk factors were based on the risk factors from the guidelines (e.g. age) combined with some general risk factors for prescribing errors (e.g. polypharmacy): age at day of hospital admission (classified into subgroups according to the guidelines' description of high-risk patients: younger than 60 years, 60-69 years, and 70 years and older) and sex of the patient, surgical ward, type of NSAID (nsNSAID or coxib), polypharmacy defined as the use of five or more drugs concomitantly, duration of NSAID use, NSAID use as needed, history of an ulcer, number of relevant comorbidities, and the use of risk medication.
Data monitoring
A sample of 10% of the entered data in this form was checked for completeness and plausibility and for checking whether the patients really exist (i.e. no false patient data included). Any systematic errors discovered in this sample were checked in the complete dataset and corrected where necessary. The complete dataset was also checked for outlier data and their validity was checked as well.
Data analysis
Data analysis was carried out using SPSS Statistics, version 21 (IBM Corp., Armonk, New York, USA).
For the sample size, at least 10 cases of guideline noncompliance are required per studied potential risk factor. Thus, we needed 100 cases for evaluating 10 potential risk factors. With an expected noncompliance rate of 40%, 250 hospital admissions were needed.
For the analysis of the primary outcome, the proportion of noncompliance with the guideline was calculated by dividing the number of hospital admissions with noncompliance by the total number of included admissions and expressed as the percentage of all included admissions. Also, proportions for each type of noncompliance were calculated, namely, PPI incorrectly added and PPI incorrectly not added. In addition, for the secondary analysis in this study, univariate and multivariable logistic regression analyses were carried out. Potential risk factors with a statistically significant association in the univariate analysis were entered into the multivariate model. When this changed the beta coefficient for at least 10%, the risk factor was retained in the model. Unadjusted and adjusted odds ratios (ORs) and their 95% confidence intervals were calculated.
Results
The study base population consisted of 3181 hospital admissions. A random subset of 480 hospital admissions was selected for screening of inclusion and exclusion criteria. In 231 hospital admissions, at least one reason for exclusion was present. Thus, 249 hospital admissions of 248 patients (one patient was admitted twice during the study period) fulfilled the inclusion criteria (Fig. 1) . Table 2 shows the baseline patient characteristics of included hospital admissions. The mean age of the admitted patients was 43.5 ( 17.7) years, with the majority of patients in the youngest age category (< 60 years). During most hospital admissions, the nsNSAID diclofenac or the COX-2 selective NSAID etoricoxib were prescribed. In 48 (19.3%) admissions, the patient received the NSAID as needed. No patients had a history of untreated infection with H. pylori. The majority of patients did not have any comorbidities or risk medication. Diabetes mellitus was recorded in 10 (4.0%) hospital admissions. In 19 (7.6%) hospital admissions, the receiving patient had risk medication together with the prescribed NSAID. In one (0.4%) hospital admission, the receiving patient had three of those medicines. There were no hospital admissions in which the patient had more than three of these medicines alongside the prescribed NSAID, nor hospital admissions in which the patient had more than one comorbidity.
Guideline noncompliance
In 116 hospital admissions, noncompliance with the guideline on NSAID use and gastroprotection was identified, resulting in a proportion of 46.6%. In 108 (43.4% of all admissions; 93.1% of noncompliant admissions) admissions, the PPI was incorrectly added and in eight (3.2% of all admissions; 6.9% of noncompliant admissions) the PPI was incorrectly not added. PPI from home (n = 90) NSAID + PPI from home (n = 48) Age<18 years (n = 9) PPI before NSAID (n = 25) Fig. 1 . Study flow. PPI, proton pump inhibitor.
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Potential risk factors for noncompliance
Unadjusted ORs of the univariate analysis of the association between several potential risk factors and noncompliance are presented in 
Discussion
This study shows that in almost half of the hospital admissions to surgical wards, PPI prescribing is not compliant with the national guidelines on NSAID use and gastroprotection. A significant inverse association of coxib use with guideline noncompliance was found in this study. This means that when a coxib is prescribed, physicians comply more with the guideline on NSAID use and gastroprotection. As coxibs form a gastroprotective strategy as such, PPIs are more often correctly not coprescribed. This study also showed that polypharmacy and specific surgical wards are associated with guideline noncompliance. With an increasing number of medicines, it may become more difficult for doctors to interpret the guideline correctly. Specific ward protocols and/or culture may explain the differences between wards. Especially, orthopedic and plastic surgery wards seem to perform less than other wards. Our study was not designed to clarify the reasons for this and studies in other hospitals are needed to confirm this finding. Nevertheless, the variation in guideline noncompliance between surgical ward types may be the focus for tailored interventions to improve compliance.
We are not aware of any other study reporting on compliance with guidelines on NSAID use and gastroprotection among patients admitted to surgical wards. However, compliance with guidelines for PPI prescriptions has been investigated in other settings [8] [9] [10] [11] 18] . These studies have shown that compliance is low and PPIs are generally underprescribed. In contrast, this study showed that PPIs are generally being overprescribed. Several studies have confirmed overprescribing of PPIs, as we have found in our study [12, 13] . One of these studies has been carried out (partly) in the same hospital as ours, but in another type of ward, namely, the pulmonary medicine ward [13] . On such a ward, NSAIDs are not used for purely postoperative reasons, as is mainly the case on the surgical wards in our study. We hypothesize that the main reason for overprescription in our study is a gap in the knowledge of the national guidelines and local protocols in the surgically oriented doctors and nurses. This can result in an unfounded fear for gastric complications. As a consequence of the very high incidence of NSAID prescription in surgical wards, the accompanying gastroprotection may occur too easily along with it ('it doesn't harm to try'). As most studies on gastrointestinal toxicity and risk factors involve patients on chronic NSAID therapy, the guidelines on gastroprotection are also based on such long-term NSAID use. Little is known on the effect of gastroprotection in short-term use of NSAIDs, making careful selection of PPI prescription even more important, especially as PPIs are often inadvertently continued even though the NSAID has been stopped. The strengths of this study are the complete medication data that are available in the computerized physician order entry system, enabling accurate retrospective assessment of drug exposure. The use of the hospital database enabled the identification of all patients prescribed NSAIDs during the study period and assessment of individual patient and treatment characteristics that are important in determination of compliance.
Some potential limitations were present in this study. First, because of the retrospective design of this study, we could have missed essential data for the determination of compliance with the guidelines. Second, indications for the prescribed PPI were not recorded most of the time. It could be the case that the patient had other symptoms and the PPI was prescribed for an indication other than as comedication with an NSAID. Therefore, we may have overestimated the number of patients with noncompliance. However, we prevented this as much as possible by excluding patients who received the PPI at least 2 h before the NSAID. In addition, most PPIs were prescribed at exactly the same time as the NSAID, rendering an alternative indication more unlikely. Third, it was not always obvious whether the patient had the NSAID or PPI or both prescribed in hospital or whether the patient had the medication already from home, adopted in hospital by the prescribing physician. This could have led to inclusion of patients who should actually have been excluded, and thus this could have led to an overestimated effect. However, determination of whether the medication was from home or not was carried out in a standardized manner. Also, as many resources as possible were used to determine whether the medication was from home; thus, we do not expect a major bias because of this. Finally, this study was carried out in a single-center setting, which may limit the generalizability of our results. However, we know that in many surgical wards, not prescribing gastroprotection together with an NSAID is more or less considered an omission. Therefore we recommend that surgeons and nurses receive better training on this subject.
In the current study, we did not investigate noncompliance with guidelines in a multicenter setting with larger numbers of patients; this is a subject for future research. Another interesting topic for future research is the investigation of coxib prescribing compliance with guidelines. Finally, additional research is necessary on interventions aimed at improving guideline compliance.
Conclusion
In conclusion, noncompliance with the national evidencebased guideline on NSAID use and PPI prescription as gastroprotection is high, mostly because PPIs are being overprescribed. Improvement is necessary and could be focused on the risk factors identified in this study. Such improvements may lead to substantial cost-savings and the prevention of PPI-related toxicity.
